TrialPloS one2012

Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

Shernan G Holtan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.